Evidence map›Paper›PMID 25246314›Full record

ArticleActa biomaterialia2015

Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA.

Corey J Bishop, Stephany Y Tzeng, Jordan J Green

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Corey J BishopDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, 400 North Broadway Rm 5017, Baltimore, MD 21231, USA.
Stephany Y TzengDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, 400 North Broadway Rm 5017, Baltimore, MD 21231, USA.
Jordan J GreenDepartment of Biomedical Engineering, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, 400 North Broadway Rm 5017, Baltimore, MD 21231, USA; Department of Neurosurgery, Johns Hopkins University School of Medicine, 400 North Broadway Rm 5017, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, 400 North Broadway Rm 5017, Baltimore, MD 21231, USA; Department of Materials Science and Engineering, Johns Hopkins University, 400 North Broadway Rm 5017, Baltimore, MD 21231, USA. Electronic address: green@jhu.edu.

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jiang Qian · 1985 to 2026
$22.1M
Gene Delivery Nanoparticles to Treat GlioblastomaR01EB016721 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2013 to 2017
$1.9M
NEI NIH HHS P30 EY001765NIBIB NIH HHS 1R01EB016721NIBIB NIH HHS R01 EB016721
6 · The paper itself

Abstract

Gold nanoparticles have utility for in vitro, ex vivo and in vivo imaging applications as well as for serving as a scaffold for therapeutic delivery and theranostic applications. Starting with gold nanoparticles as a core, layer-by-layer degradable polymer coatings enable the simultaneous co-delivery of DNA and short interfering RNA (siRNA). To engineer release kinetics, polymers which degrade through two different mechanisms can be utilized to construct hybrid inorganic/polymeric particles. During fabrication of the nanoparticles, the zeta potential reverses upon the addition of each oppositely charged polyelectrolyte layer and the final nanoparticle size reaches approximately 200nm in diameter. When the hybrid gold/polymer/nucleic acid nanoparticles are added to human primary brain cancer cells in vitro, they are internalizable by cells and reach the cytoplasm and nucleus as visualized by transmission electron microscopy and observed through exogenous gene expression. This nanoparticle delivery leads to both exogenous DNA expression and siRNA-mediated knockdown, with the knockdown efficacy superior to that of Lipofectamine® 2000, a commercially available transfection reagent. These gold/polymer/nucleic acid hybrid nanoparticles are an enabling theranostic platform technology capable of delivering combinations of genetic therapies to human cells.

Indexed as

Absorbable ImplantsAbsorption, PhysicochemicalAgedBrain NeoplasmsCoated Materials, BiocompatibleDiffusionDNADrug ImplantsGene SilencingGenetic TherapyGoldHumansMaleMaterials TestingMetal NanoparticlesNanocompositesCoated Materials, BiocompatibleDNADrug ImplantsGoldPolymersRNA, Small InterferingCo-deliverGene deliveryGoldLayer-by-layerNanoparticle

Identifiers

PMID25246314
PMCPMC4289153

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.